Mefway (18F)
Mefway (18F) is a radioligand used in positron emission tomography (PET) imaging. It is a fluorine-18 labeled analog of WAY-100635, a potent and selective antagonist of the serotonin 5-HT1A receptor. Mefway (18F) is used to visualize and quantify the distribution of 5-HT1A receptors in the human brain.
History[edit]
Mefway (18F) was first synthesized in the early 2000s as part of a broader effort to develop new radioligands for PET imaging of the serotonin system. The development of Mefway (18F) was motivated by the need for a radioligand with improved properties compared to existing 5-HT1A receptor PET tracers, such as [[11C]WAY-100635]].
Chemistry[edit]
Mefway (18F) is a fluorinated analog of WAY-100635. The fluorine-18 isotope is incorporated into the molecule via a nucleophilic substitution reaction. The resulting compound is a potent and selective antagonist of the 5-HT1A receptor, with a high affinity for this receptor subtype.
Pharmacology[edit]
Mefway (18F) binds selectively to the 5-HT1A receptor, allowing for the visualization and quantification of this receptor subtype in the brain. The binding of Mefway (18F) to the 5-HT1A receptor is reversible, which is a desirable property for a PET radioligand.
Clinical Use[edit]
Mefway (18F) is used in PET imaging to study the distribution and density of 5-HT1A receptors in the human brain. This can be useful in research and clinical settings, for example, to investigate the role of the serotonin system in psychiatric and neurological disorders.
See Also[edit]
Mefway (18F)[edit]
-
Mefway 18F skeletal
-
Mefway cis-trans comparison
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
